Response to neoadjuvant selpercatinib in a pediatric patient with advanced papillary thyroid carcinoma: a case report

Pediatric Hematology and Oncology · Published 2025-03-03 · DOI 10.1080/08880018.2025.2466022

Authors being retrieved — see the publisher record. https://doi.org/10.1080/08880018.2025.2466022

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

Pediatric AML: state of the Art and Future Directions · Pediatric Hematology and Oncology · 2025 · Same journal
HSCT Conditioning for Children: The Art in the Science · Pediatric Hematology and Oncology · 2026 · Same journal
Prevalence of plasma coagulation deficiencies and antiphospholipid antibodies positivity in the pediatric population of the Małopolska region: A single-center study from a pediatric hospital in Kraków · Pediatric Hematology and Oncology · 2026 · Same journal
The burden of childhood cancer in Nigeria – a focus on leukemia and lymphoma: epidemiology, biology, and health system challenges · Pediatric Hematology and Oncology · 2026 · Same journal
Prognostic value of serum albumin recovery in pediatric cancer patients: insights into cancer-cachexia and survival outcomes · Pediatric Hematology and Oncology · 2026 · Same journal
Bone mineral status at diagnosis οf children with hematologic malignancy · Pediatric Hematology and Oncology · 2025 · Same journal
Step-down management of fever and neutropenia in low-risk pediatric and adolescent-young adult oncology patients is safe and effective: a single center experience · Pediatric Hematology and Oncology · 2025 · Same journal
Parental and Patients’ Awareness, Knowledge, and Willingness for Human Papillomavirus Vaccination Among Survivors of Childhood Hematologic Malignancies · Pediatric Hematology and Oncology · 2026 · Same journal
Clofarabine monotherapy in refractory multisystem LCH with gastrointestinal involvement · Pediatric Hematology and Oncology · 2025 · Same journal
Prepubertal Initiation of Imatinib is Associated with Reduced Final Height in Children with Chronic Myeloid Leukemia · Pediatric Hematology and Oncology · 2026 · Same journal